Previously our group was able to show that DC injected via different routes activate CD8+ T cells at different sites and imprint homing receptors corresponding to the site of priming [16] We were now interested if these differently primed T cells are able to migrate to distinct target tissues in vivo and if they are able to prevent subcutaneously (s.c.)growing melanoma with different potencies. The gene discussed is CD8A; the disease is melanoma.